**Supplementary Table 1. Grade of evidence about terlipressin compared to no active drug for hepatorenal syndrome**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Terlipressin compared to no active drug for hepatorenal syndrome** | | | | | | |
| **Patient or population:** patients with hepatorenal syndrome **Settings:** hospital **Intervention:** terlipressin **Comparison:** no active drug | | | | | | |
| **Outcomes** | **Illustrative comparative risks\* (95% CI)** | | **Relative effect (95% CI)** | **No of Participants (studies)** | **Quality of the evidence (GRADE)** | **Comments** |
| Assumed risk | Corresponding risk |
|  | **No active drug** | **Terlipressin** |  |  |  |  |
| **HRS reversal** | **Study population** | | **RR 2.54**  (1.73 to 3.72) | 406 (4 studies) | ⊕⊕⊝⊝ **low**1,2 | Downgraded because of  risk of bias and inconsistency. |
| **142 per 1000** | **361 per 1000** (246 to 529) |
| **Moderate** | |
| **138 per 1000** | **351 per 1000** (239 to 513) |
| **survival** | **Study population** | | **RR 1.1**  (0.89 to 1.37) | 354 (3 studies) | ⊕⊝⊝⊝ **very low**1,2,3 | Downgraded because of  risk of bias and inconsistency. |
| **444 per 1000** | **488 per 1000** (395 to 608) |
| **Moderate** | |
| **375 per 1000** | **412 per 1000** (334 to 514) |
| **serious adverse event** | **Study population** | | **RR 1.24**  (0.98 to 1.58) | 352 (3 studies) | ⊕⊝⊝⊝ **very low**1,2,3 | Downgraded because of  risk of bias and inconsistency. |
| **305 per 1000** | **378 per 1000** (299 to 482) |
| **Moderate** | |
| **18 per 1000** | **22 per 1000** (18 to 28) |
| \*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio; | | | | | | |
| GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate. | | | | | | |
| 1 risk of bias 2 small patients 3 outcomes different | | | | | | |